Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Ajanta Pharma is currently trading at Rs. 298.05, up by 1.20 points or 0.40% from its previous closing of Rs. 296.85 on the BSE.
The scrip opened at Rs. 296.00 and has touched a high and low of Rs. 302.00 and Rs. 289.10 respectively. So far 3,883 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 368.00 on 22-Jul-2011 and a 52 week low of Rs. 172.00 on 18-Jan-2011.
Last one week high and low of the scrip stood at Rs. 330.00 and Rs. 289.10 respectively. The current market cap of the company is Rs. 348.00 crore.
The promoters holding in the company stood at 66.82% while Institutions and Non-Institutions held 0.32% and 32.86% respectively.
Credit rating agency, CARE has reaffirmed the assigned ‘A+/A1’ rating to long-term/short-term bank facilities of Ajanta Pharma for Rs 120.00 crore. The agency has also reaffirmed the assigned ‘A1’ rating to the short-term bank facilities of the company for Rs 35.00 crore.
Further, the agency has also reaffirmed the assigned ‘A+’ rating to long-term loans of the company for Rs 67.87 crore.
The ability of the company to achieve the projected sales and profitability remain the key rating sensitivities. However, the ratings continue to be constrained by the long working capital cycle, volatile nature of raw material prices and increasing competition in the domestic formulation market from multinationals and Indian drug manufacturers.
Ajanta Pharma is engaged in manufacturing and marketing of pharmaceutical formulations. The company’s product portfolio includes around 200 active products including line extensions catering to various therapeutic segments including Cardiovascular Diseases (CVD), Dermatology, Pediatrics, Ophthalmology, Nephrology, Orthopaedic, amongst others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1532.00 |
| Dr. Reddys Lab | 5780.70 |
| Cipla | 1442.00 |
| Zydus Lifesciences | 1088.45 |
| Lupin | 1683.50 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
